Adherex Technologies Inc. Receives FDA Orphan Drug Designation For Eniluracil In Liver Cancer: Designation Provides Up To Seven Years Of Market Exclusivity Upon Regulatory Approval

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Dec. 21, 2005--Adherex Technologies Inc. (AMEX:ADH)(TSX:AHX), a biopharmaceutical company with a broad portfolio of oncology products under development, today announced that it has received orphan drug designation for eniluracil from the U.S. Food and Drug Administration (FDA). The designation was granted for the use of eniluracil in combination with fluoropyrimidines for the treatment of hepatocellular cancer. The fluoropyrimidines include 5-fluorouracil (5-FU) and other 5-FU prodrugs. Adherex’s global development plans for eniluracil, announced on November 16, 2005, include clinical trials in hepatocellular cancer.

MORE ON THIS TOPIC